Genprex (NASDAQ:GNPX) Trading Down 5% – Here’s Why

Genprex (NASDAQ:GNPX) shares were down 5% on Monday . The company traded as low as $3.90 and last traded at $4.00. Approximately 240,448 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 1,794,013 shares. The stock had previously closed at $4.21.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GNPX. Wall Street Zen raised Genprex to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Genprex Price Performance

The firm’s 50 day moving average price is $10.69 and its two-hundred day moving average price is $12.11. The firm has a market cap of $5 million, a price-to-earnings ratio of -0.05 and a beta of -0.74.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($8.50) EPS for the quarter, beating the consensus estimate of ($35.50) by $27.00. On average, analysts anticipate that Genprex will post -5.7 earnings per share for the current year.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.